



- (51) **International Patent Classification:**  
*C07K 14/55* (2006.01)
- (21) **International Application Number:**  
PCT/EP2021/083864
- (22) **International Filing Date:**  
02 December 2021 (02.12.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
20211731.3 04 December 2020 (04.12.2020) EP
- (71) **Applicant (for all designated States except US): F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).
- (71) **Applicant (for US only): HOFFMANN-LA ROCHE INC.** [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US).
- (72) **Inventors: DEHÒ, Lorenzo;** c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **GASSNER, Christian;** c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **HERTER, Sylvia;** c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **HOFFER, Thomas;** c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (DE). **HOSSE, Ralf;** c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **HUGENMATTER, Adrian;** c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **KLEIN, Christian;** c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **LIMANI, Florian;** c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **MOESSNER, Ekkehard;** c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **OBBA, Melanie;** c/o Roche Glycart AG, Wag-

istrasse 10, 8952 Schlieren (CH). **SCHERER, Bianca;** c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **UMAÑA, Pablo;** c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH).

- (74) **Agent: KASCHAU, Nikolai;** F. Hoffmann-La Roche AG, Patent Department, Grenzacherstrasse 124, 4070 Basel (CH).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— of inventorship (Rule 4.17(iv))

- (54) **Title:** PH-DEPENDENT MUTANT INTERLEUKIN-2 POLYPEPTIDES

**Figure 1**



(57) **Abstract:** The present invention generally relates to pH-dependent mutant interleukin-2 polypeptides that exhibit reduced IL-2 receptor binding at neutral pH and retain IL-2 receptor binding at reduced pH. In addition, the invention relates to immunoconjugates comprising said pH-dependent mutant IL-2 polypeptides, polynucleotide molecules encoding the pH-dependent mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the pH-dependent mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.

[Continued on next page]

**Published:**

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*